Quest Diagnostics has announced the availability of a new risk assessment and care plan service across the US, called RestoreU Dementia Panel.
The availability was made through a partnership between Quest and uMETHOD Health, creator of the RestoreU service.
Go deeper with GlobalData
RestoreU uses artificial intelligence (AI) to make tailor-made care plans that intend to help physicians improve patient care and comply with cognitive care guidelines.
It complements Quest’s dementia laboratory services portfolio that comprises the company’s AD-Detect Amyloid Beta (AB) 42/40 Ratio blood test to evaluate the risk of Alzheimer’s disease.
The service features results of laboratory tests ordered by Quest Diagnostics physicians. It also includes the patient’s health history such as comorbidities, lifestyle habits and medications.
Leveraging these data, the AI platform of uMETHOD then evaluates more than 50 risk factors to indicate areas of concern and eventually create a personalised care plan that comprises evidence-driven and necessary treatment suggestions.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataPhysicians can use data from the report to identify possible reversible causes of cognitive decline, such as medication side effects or hormonal imbalances that replicate dementia.
The personalised care plans could cover pharmacological and supplementation-based treatment as well as lifestyle habit suggestions that can be used by the physician to counsel the patient.
RestoreU has been designed as an adjunct service, not as a replacement for the physician’s judgment, according to Quest.
Quest Diagnostics Neurology medical director Michael Racke said: “With so much attention on emerging therapies for Alzheimer’s disease, it is easy to overlook the growing body of science suggesting a preventive care approach can help delay the onset of Alzheimer’s and other dementias in some patients.
“In addition, not all cognitive disorders signify dementia and may, in some cases, be due to reversible causes.
“RestoreU provides robust personalised insights to help the physician tease out the confounding factors causing a patient’s cognitive decline and identify measures that may help improve care and outcomes.”
